BioMimetic Therapeutics, a developer of bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, plans to offer 4.5 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will have an initial market capitalization of $186 million. Deutsche Bank and Pacific Growth Equities are the lead managers on the deal. Timing has yet to be announced.
